GB1445983A - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB1445983A
GB1445983A GB5105072A GB5105072A GB1445983A GB 1445983 A GB1445983 A GB 1445983A GB 5105072 A GB5105072 A GB 5105072A GB 5105072 A GB5105072 A GB 5105072A GB 1445983 A GB1445983 A GB 1445983A
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
nov
allopurinol
heading
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5105072A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GB5105072A priority Critical patent/GB1445983A/en
Priority to AU62177/73A priority patent/AU467532B2/en
Priority to IL43562A priority patent/IL43562A/en
Priority to FR7339183A priority patent/FR2205309B1/fr
Priority to DE19732355204 priority patent/DE2355204A1/en
Priority to ZA00738489A priority patent/ZA738489B/en
Priority to CA185,010A priority patent/CA975297A/en
Priority to CH1552773A priority patent/CH583734A5/xx
Priority to JP12430373A priority patent/JPS577127B2/ja
Priority to CY940A priority patent/CY940A/en
Priority to BE137437A priority patent/BE806946A/en
Publication of GB1445983A publication Critical patent/GB1445983A/en
Priority to KE2807A priority patent/KE2807A/en
Priority to HK12/78A priority patent/HK1278A/en
Priority to MY1978180A priority patent/MY7800180A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1445983 Compositions containing allopurinol WELLCOME FOUNDATION Ltd 5 Nov 1973 [6 Nov 1972] 51050/72 Heading A5B A tablet formulation comprises from 55 % to 79% (w/w) of allopurinol having a particle size, as defined, less than 40Ám, from 15 to 35% (w/w) of an inert filler, from 5 to 15% (w/w) of a disintegrating agent and from 1 to 10% w/w of a granulating agent.
GB5105072A 1972-11-06 1972-11-06 Pharmaceutical formulations Expired GB1445983A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB5105072A GB1445983A (en) 1972-11-06 1972-11-06 Pharmaceutical formulations
CH1552773A CH583734A5 (en) 1972-11-06 1973-11-05
JP12430373A JPS577127B2 (en) 1972-11-06 1973-11-05
FR7339183A FR2205309B1 (en) 1972-11-06 1973-11-05
DE19732355204 DE2355204A1 (en) 1972-11-06 1973-11-05 PHARMACEUTICAL PREPARATIONS CONTAINING ALLOPURINOL AND THE METHOD FOR THEIR MANUFACTURING
ZA00738489A ZA738489B (en) 1972-11-06 1973-11-05 Pharmaceutical formulations
CA185,010A CA975297A (en) 1972-11-06 1973-11-05 Pharmaceutical composition containing a high percentage of allopurinol
AU62177/73A AU467532B2 (en) 1972-11-06 1973-11-05 Pharmaceutical formulations
IL43562A IL43562A (en) 1972-11-06 1973-11-05 Pharmaceutical formulations containing allopurinol as inhibitor of xanthine oxidase
CY940A CY940A (en) 1972-11-06 1973-11-05 Pharmaceutical formulations
BE137437A BE806946A (en) 1972-11-06 1973-11-05 PHARMACEUTICAL COMPOSITIONS CONTAINING XANTHINE OXIDASE INHIBITORS
KE2807A KE2807A (en) 1972-11-06 1977-12-02 Pharmaceutical formulations
HK12/78A HK1278A (en) 1972-11-06 1978-01-05 Pharmaceutical formulations
MY1978180A MY7800180A (en) 1972-11-06 1978-12-31 Pharmaceutical formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5105072A GB1445983A (en) 1972-11-06 1972-11-06 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
GB1445983A true GB1445983A (en) 1976-08-11

Family

ID=10458450

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5105072A Expired GB1445983A (en) 1972-11-06 1972-11-06 Pharmaceutical formulations

Country Status (14)

Country Link
JP (1) JPS577127B2 (en)
AU (1) AU467532B2 (en)
BE (1) BE806946A (en)
CA (1) CA975297A (en)
CH (1) CH583734A5 (en)
CY (1) CY940A (en)
DE (1) DE2355204A1 (en)
FR (1) FR2205309B1 (en)
GB (1) GB1445983A (en)
HK (1) HK1278A (en)
IL (1) IL43562A (en)
KE (1) KE2807A (en)
MY (1) MY7800180A (en)
ZA (1) ZA738489B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1499672A (en) * 1974-02-14 1978-02-01 Wellcome Found Tablet formulation
US4143129A (en) 1975-10-11 1979-03-06 Lilly Industries Limited Cephalexin tablets
FR2608045B1 (en) * 1986-12-12 1990-03-02 Chauvin Laboratoires USE OF XANTHINE OXIDASE INHIBITORS, OXYGEN FREE RADIAL TRAPERS AND IRON CHELATORS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors

Also Published As

Publication number Publication date
CY940A (en) 1978-06-23
AU467532B2 (en) 1975-12-04
IL43562A0 (en) 1974-03-14
DE2355204A1 (en) 1974-05-16
IL43562A (en) 1976-08-31
FR2205309A1 (en) 1974-05-31
BE806946A (en) 1974-05-06
CA975297A (en) 1975-09-30
JPS49133517A (en) 1974-12-21
CH583734A5 (en) 1977-01-14
MY7800180A (en) 1978-12-31
JPS577127B2 (en) 1982-02-09
FR2205309B1 (en) 1976-04-09
ZA738489B (en) 1975-02-26
AU6217773A (en) 1975-05-08
KE2807A (en) 1978-02-17
HK1278A (en) 1978-01-13

Similar Documents

Publication Publication Date Title
GB1405088A (en) Slow release formulation
GB1380171A (en) Medicinal tablets
ES269650A1 (en) Silica-gel powder tablet compositions
GB1464200A (en) Pharmaceutical composition
GB1445983A (en) Pharmaceutical formulations
GB1457546A (en) Pharmaceutical preparations comprising cephalosporin derivatives
GB1533243A (en) Tablet formulation
GB1442159A (en) Pharmaceutical compositions containing paracetamol
GB1270049A (en) New pharmaceutical product
GB1270752A (en) Dentifrice compositions
GB1126153A (en) Novel polygalacturonic acid derivative
FR7536M (en)
GB1203328A (en) Pharmaceutical compositions
CA958643A (en) Pharmaceutical compositions containing cyclobenzaprine
IL37116A0 (en) Pharmaceutical compositions containing derivatives of l-(3,4-dihydroxy-phenyl)alanine
GB1327560A (en) Effervescent pharmaceutical preparations
GB1357813A (en) Effervescent composition for the treatment of heart diseases
IL32085A (en) P-(pyrryl-1)-phenethyl alcohols and their esters,their preparation and pharmaceutical compositions containing them
GB1287433A (en) Pharmaceutical compositions
GB1298587A (en) Methods of contraception and contraceptive compositions
GB1021070A (en) A new triazolone and a process for its preparation
GB1301849A (en)
GB1446237A (en) Pharmaceutical preparations containing pyrazolones
GB1465771A (en) Pharmaceutical composition and use thereofd
GB1233150A (en)

Legal Events

Date Code Title Description
416 Proceeding under section 16 patents act 1949
PS Patent sealed [section 19, patents act 1949]
PE20 Patent expired after termination of 20 years

Effective date: 19931104